Publications by authors named "Livia C Lins"
Article Synopsis
- - α-Synuclein is believed to play a significant role in causing Parkinson's disease, leading to neurodegeneration and cell death through its aggregation.
- - Researchers used a method called RNA interference with specific siRNA sequences to reduce human α-synuclein levels in mice, particularly focusing on one effective sequence called miSyn4.
- - The study showed that delivering miSyn4 via AAV vectors not only reduced human α-synuclein levels but also improved behavioral issues in the mice, suggesting a potential therapeutic approach for treating Parkinson's disease.
Aims: The aim of this work was to evaluate the effects of treatment of hypertension on the autoantibodies to apolipoprotein B-derived peptides (anti-ApoB-D peptide Abs) response, inflammation markers and vascular function.
Main Methods: Eighty-eight patients with hypertension (stage 1 or 2) were recruited and advised to receive perindopril (4mg), hydrochlorothiazide (25mg), or indapamide (1.5mg) for 12weeks in a blinded fashion.
Imbalance on endothelial turnover can predict cardiovascular outcomes. We aimed at evaluating the effects of lipid-modifying therapies on circulating endothelial progenitor cells (EPCs), endothelial microparticles (EMPs), and platelet microparticles (PMPs) in high cardiovascular risk subjects with elevated C-reactive protein (CRP). Sixty-three individuals with coronary heart disease (CHD) or CHD risk equivalent on stable statin therapy, with LDL-cholesterol <100 mg/dL and CRP ≥ 2.
View Article and Find Full Text PDFAims: High-risk subjects with elevated C-reactive protein (CRP) are at high risk for cardiovascular events and frequently require potent statins or combined lipid-lowering therapy to achieve lipid targets and decrease inflammation. Our study aimed at evaluating the effects of three lipid-modifying therapies on LDL-cholesterol, CRP levels and markers of cholesterol absorption and synthesis.
Main Methods: A prospective intervention study was performed in high cardiovascular risk individuals receiving atorvastatin 10mg daily for four weeks.